{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:39:18Z","timestamp":1790390358794,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente Funds Inst. Pascale Prog. M3\/6"],"award-info":[{"award-number":["Ricerca Corrente Funds Inst. Pascale Prog. M3\/6"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente Funds Inst. Pascale Prog. M4\/3"],"award-info":[{"award-number":["Ricerca Corrente Funds Inst. Pascale Prog. M4\/3"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["POR CAMPANIA FESR 2014\/2020 Progetto: Campania Onco-Terapie CUP: 631 B61G18000470007"],"award-info":[{"award-number":["POR CAMPANIA FESR 2014\/2020 Progetto: Campania Onco-Terapie CUP: 631 B61G18000470007"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["FIRC-AIRC supported with a triennial Fellowship F. Iannelli (ID 22648)"],"award-info":[{"award-number":["FIRC-AIRC supported with a triennial Fellowship F. Iannelli (ID 22648)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["FIRC-AIRC supported with a triennial Fellowship MS. Roca (ID 21113)"],"award-info":[{"award-number":["FIRC-AIRC supported with a triennial Fellowship MS. Roca (ID 21113)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["FIRC-AIRC supported with a triennial Fellowship C. Ciardiello (ID 19586)"],"award-info":[{"award-number":["FIRC-AIRC supported with a triennial Fellowship C. Ciardiello (ID 19586)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00732","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:57:07Z","timestamp":1597669027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance"],"prefix":"10.3389","volume":"8","author":[{"given":"Federica","family":"Iannelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ilaria","family":"Zotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grumetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"De Cecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Iachetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Valiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Ionna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caponigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2020.01.008","article-title":"DNA damage response and resistance of cancer stem cells.","volume":"474","author":"Abad","year":"2020","journal-title":"Cancer Lett."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.","volume":"1","author":"Arce","year":"2006","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-875","article-title":"Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid\u2013short Radiotherapy\u2013rectum 3rd trial).","volume":"14","author":"Avallone","year":"2014","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1038\/sj.onc.1205980","article-title":"Cisplatin-induced activation of the EGF receptor.","volume":"21","author":"Benhar","year":"2002","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00405-015-3710-x","article-title":"The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.","volume":"273","author":"Bisof","year":"2016","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/annonc\/mdx439","article-title":"A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck.","volume":"28","author":"Bossi","year":"2017","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1535-7163.MCT-13-1021","article-title":"Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.","volume":"13","author":"Brand","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/1078-0432.CCR-05-1671","article-title":"Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.","volume":"12","author":"Bruzzese","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.","volume":"226","author":"Bruzzese","year":"2011","journal-title":"J. Cell Physiol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.406","article-title":"Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.","volume":"4","author":"Bruzzese","year":"2013","journal-title":"Cell Death Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","article-title":"Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.","volume":"8","author":"Bruzzese","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"viii167","DOI":"10.1093\/annonc\/mdy281.045","article-title":"Phase I\/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3).","volume":"29","author":"Budillon","year":"2018","journal-title":"Ann. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/157489207780832450","article-title":"Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.","volume":"2","author":"Budillon","year":"2007","journal-title":"Recent. Pat Anticancer. Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(13)70085-8","article-title":"Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.","volume":"14","author":"Burtness","year":"2013","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2957-y","article-title":"Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.","volume":"16","author":"Caponigro","year":"2016","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-16-3153","article-title":"Homeobox B9 mediates resistance to Anti-VEGF therapy in colorectal cancer patients.","volume":"23","author":"Carbone","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071506","article-title":"Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy.","volume":"18","author":"Castilho","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid.","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/pcmedi\/pbz016","article-title":"Targeting cancer stem cells in squamous cell carcinoma.","volume":"2","author":"Chen","year":"2019","journal-title":"Precis Clin. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck Cancer.","volume":"382","author":"Chow","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"19559","DOI":"10.18632\/oncotarget.7195","article-title":"Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.","volume":"7","author":"Ciardiello","year":"2016","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-019-0394-9","article-title":"Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for DeltaNp63alpha.","volume":"120","author":"Citro","year":"2019","journal-title":"Br. J .Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.","volume":"329","author":"Diyabalanage","year":"2013","journal-title":"Cancer Lett."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: past, present and future.","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Cell Death Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2019.1705731","article-title":"Histone deacetylases facilitate the accurate repair of broken forks.","volume":"7","author":"Gomez-Gonzalez","year":"2020","journal-title":"Mol. Cell Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","article-title":"Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer.","volume":"48","author":"Haigentz","year":"2012","journal-title":"Oral. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.canlet.2012.01.011","article-title":"Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.","volume":"318","author":"Han","year":"2012","journal-title":"Cancer Lett."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1080-8","article-title":"Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.","volume":"38","author":"He","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.canlet.2017.10.023","article-title":"Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1.","volume":"414","author":"Huang","year":"2018","journal-title":"Cancer Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/jop.12545","article-title":"Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.","volume":"46","author":"Jedlinski","year":"2017","journal-title":"J. Oral. Pathol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.freeradbiomed.2015.07.155","article-title":"Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.","volume":"89","author":"Leone","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/onc.2009.234","article-title":"Nuclear EGFR contributes to acquired resistance to cetuximab.","volume":"28","author":"Li","year":"2009","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100376","article-title":"Molecular markers of anticancer drug resistance in head and neck squamous cell carcinoma: a literature review.","volume":"10","author":"Lopez-Verdin","year":"2018","journal-title":"Cancers"},{"key":"B37","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer. Res."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091080","article-title":"Activity and trafficking of copper-transporting atpases in tumor development and defense against platinum-based drugs.","volume":"8","author":"Petruzzelli","year":"2019","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-18-1117","article-title":"Vorinostat potentiates 5-Fluorouracil\/Cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing cisplatin uptake.","volume":"18","author":"Piro","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-05-0420","article-title":"Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.","volume":"11","author":"Psyrri","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B41","first-page":"1181","article-title":"Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.","volume":"30","author":"Rikiishi","year":"2007","journal-title":"Int. J. Oncol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070912","article-title":"Implication for cancer stem cells in solid cancer chemo-resistance: promising therapeutic strategies based on the Use of HDAC inhibitors.","volume":"8","author":"Roca","year":"2019","journal-title":"J. Clin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.04.011","article-title":"Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); a new perspective in the era of immunotherapy.","volume":"115","author":"Saba","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41418-019-0289-6","article-title":"Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.","volume":"26","author":"Siddiqui","year":"2019","journal-title":"Cell Death Differ."},{"key":"B45","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/2211-5463.12585","article-title":"Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM\/p53 pathway.","volume":"9","author":"Sun","year":"2019","journal-title":"FEBS Open Bio"},{"key":"B46","doi-asserted-by":"publisher","first-page":"16036","DOI":"10.18632\/oncotarget.13917","article-title":"The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets.","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi.","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0879-4","article-title":"Immunotherapy in head and neck cancer: aiming at EXTREME precision.","volume":"15","author":"Szturz","year":"2017","journal-title":"BMC Med."},{"key":"B49","first-page":"499","article-title":"Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc.","volume":"4","author":"Tadokoro","year":"1989","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1158\/1078-0432.CCR-06-0705","article-title":"Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.","volume":"12","author":"Tan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","article-title":"A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.","volume":"37","author":"Teknos","year":"2019","journal-title":"Invest. New Drugs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0647-5","article-title":"Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.","volume":"36","author":"Terranova-Barberio","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.18632\/oncotarget.6802","article-title":"Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.","volume":"7","author":"Terranova-Barberio","year":"2016","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0636-8","article-title":"Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-kappaB-TNFalpha-PIK3CA loop.","volume":"36","author":"Thakur","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2016.11.019","article-title":"Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.","volume":"103","author":"To","year":"2017","journal-title":"Lung. Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer.","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.409","article-title":"Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1\/HDAC activity.","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153663","article-title":"Additive pharmacological interaction between cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) in MDA-MB-231 triple negative breast cancer (TNBC) cells with altered Notch1 activity-an isobolographic analysis.","volume":"20","author":"Wawruszak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s13577-019-00295-9","article-title":"CCND1 silencing suppresses liver cancer stem cell differentiation through inhibiting autophagy.","volume":"33","author":"Zhang","year":"2020","journal-title":"Hum. Cell"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:57:13Z","timestamp":1597669033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":59,"alternative-id":["10.3389\/fcell.2020.00732"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00732","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"article-number":"732"}}